Jason Gotlib

Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin

Abstract Advanced systemic mastocytosis (AdvSM) is driven by KIT D816V in approximately 95% of cases. Accurate assessment and prediction of clinical course and disease outcome before and during treatment with the KIT inhibitors midostaurin and avapritinib may facilitate optimizat...